Final Decision on Sipuleucel-T
The Centers for Medicare & Mediaid Services (CMS) issued a final decision to cover FDA-approved indications of sipuleucel-T (Provenge) in prostate cancer, calling the treatment “reasonable and necessary.” The CMS final decision assures provider reimbursement of sipuleucel-T for Medicare beneficiaries effective immediately. Cost for the complete course of therapy is $93,000.
FDA approved sipuleucel-T in April 2010 for asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. ■